(WVE) Wave Life Sciences - Overview
Stock: RNA Editing, Obesity, Duchenne, Huntington
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 86.0% |
| Relative Tail Risk | -15.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.56 |
| Alpha | -6.53 |
| Character TTM | |
|---|---|
| Beta | 1.067 |
| Beta Downside | 2.474 |
| Drawdowns 3y | |
|---|---|
| Max DD | 66.67% |
| CAGR/Max DD | 0.69 |
Description: WVE Wave Life Sciences January 15, 2026
Wave Life Sciences Ltd. (NASDAQ: WVE) is a Singapore-based, clinical-stage biotech that leverages its PRISM platform to design and develop RNA-based medicines across multiple modalities. The pipeline includes WVE-006 (RNA editing for alpha-1 antitrypsin deficiency), WVE-007 (GalNAc-siRNA targeting INHBE for obesity), WVE-N531 (exon-skipping for Duchenne muscular dystrophy), and WVE-003 (allele-selective oligonucleotide for Huntington’s disease). The company has strategic collaborations with GlaxoSmithKline, Takeda, and Asuragen to co-develop and potentially commercialize oligonucleotide therapeutics and companion diagnostics.
From a market perspective, the global RNA therapeutics sector is projected to grow at a ~15% CAGR through 2030, driven by expanding FDA approvals and the scalability of oligonucleotide chemistry. As of Q3 2024, Wave reported a cash runway of roughly $80 million, sufficient to fund its current R&D milestones without immediate dilution. Recent pre-clinical data for WVE-007 demonstrated a 30% reduction in weight gain in obese mouse models, supporting its potential as a first-in-class obesity treatment, while the GSK partnership includes up to $200 million in milestone payments tied to development and commercialization milestones.
For a deeper quantitative view of Wave’s valuation metrics and scenario analysis, the ValueRay platform offers a concise, data-driven dashboard worth checking out.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -121.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.82 > 0.02 and ΔFCF/TA -42.54 > 1.0 |
| NWC/Revenue: 118.6% < 20% (prev 286.9%; Δ -168.2% < -1%) |
| CFO/TA -0.82 > 3% & CFO -197.4m > Net Income -121.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (167.7m) vs 12m ago 26.54% < -2% |
| Gross Margin: 35.83% > 18% (prev 0.84%; Δ 3499 % > 0.5%) |
| Asset Turnover: 36.42% > 50% (prev 14.95%; Δ 21.46% > 0%) |
| Interest Coverage Ratio: -11.60 > 6 (EBITDA TTM -124.7m / Interest Expense TTM -11.5m) |
Altman Z'' -15.00
| A: 0.54 (Total Current Assets 215.5m - Total Current Liabilities 85.9m) / Total Assets 241.4m |
| B: -5.27 (Retained Earnings -1.27b / Total Assets 241.4m) |
| C: -0.44 (EBIT TTM -133.4m / Avg Total Assets 299.9m) |
| D: -0.42 (Book Value of Equity -49.5m / Total Liabilities 116.8m) |
| Altman-Z'' Score: -17.11 = D |
Beneish M -1.12
| DSRI: 0.23 (Receivables 10.0m/21.1m, Revenue 109.2m/53.6m) |
| GMI: 2.34 (GM 35.83% / 83.79%) |
| AQI: 1.44 (AQ_t 0.02 / AQ_t-1 0.01) |
| SGI: 2.04 (Revenue 109.2m / 53.6m) |
| TATA: 0.31 (NI -121.9m - CFO -197.4m) / TA 241.4m) |
| Beneish M-Score: -1.12 (Cap -4..+1) = D |
What is the price of WVE shares?
Over the past week, the price has changed by +3.94%, over one month by -11.22%, over three months by +70.69% and over the past year by +13.60%.
Is WVE a buy, sell or hold?
- StrongBuy: 9
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the WVE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32.4 | 140.9% |
| Analysts Target Price | 32.4 | 140.9% |
| ValueRay Target Price | 16.2 | 20.5% |
WVE Fundamental Data Overview February 03, 2026
P/B = 19.4039
Revenue TTM = 109.2m USD
EBIT TTM = -133.4m USD
EBITDA TTM = -124.7m USD
Long Term Debt = 19.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 8.39m USD (from shortTermDebt, last quarter)
Debt = 19.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -176.4m USD (from netDebt column, last quarter)
Enterprise Value = 2.23b USD (2.40b + Debt 19.8m - CCE 196.2m)
Interest Coverage Ratio = -11.60 (Ebit TTM -133.4m / Interest Expense TTM -11.5m)
EV/FCF = -11.24x (Enterprise Value 2.23b / FCF TTM -198.2m)
FCF Yield = -8.90% (FCF TTM -198.2m / Enterprise Value 2.23b)
FCF Margin = -181.4% (FCF TTM -198.2m / Revenue TTM 109.2m)
Net Margin = -111.6% (Net Income TTM -121.9m / Revenue TTM 109.2m)
Gross Margin = 35.83% ((Revenue TTM 109.2m - Cost of Revenue TTM 70.1m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 74.76%)
Tobins Q-Ratio = 9.23 (Enterprise Value 2.23b / Total Assets 241.4m)
Interest Expense / Debt = 14.57% (Interest Expense 2.88m / Debt 19.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -105.4m (EBIT -133.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.51 (Total Current Assets 215.5m / Total Current Liabilities 85.9m)
Debt / Equity = 0.16 (Debt 19.8m / totalStockholderEquity, last quarter 124.5m)
Debt / EBITDA = 1.41 (negative EBITDA) (Net Debt -176.4m / EBITDA -124.7m)
Debt / FCF = 0.89 (negative FCF - burning cash) (Net Debt -176.4m / FCF TTM -198.2m)
Total Stockholder Equity = 161.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.66% (Net Income -121.9m / Total Assets 241.4m)
RoE = -75.61% (Net Income TTM -121.9m / Total Stockholder Equity 161.3m)
RoCE = -73.71% (EBIT -133.4m / Capital Employed (Equity 161.3m + L.T.Debt 19.8m))
RoIC = -65.37% (negative operating profit) (NOPAT -105.4m / Invested Capital 161.3m)
WACC = 9.86% (E(2.40b)/V(2.42b) * Re(9.85%) + D(19.8m)/V(2.42b) * Rd(14.57%) * (1-Tc(0.21)))
Discount Rate = 9.85% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 23.70%
Fair Price DCF = unknown (Cash Flow -198.2m)
EPS Correlation: 51.26 | EPS CAGR: 131.1% | SUE: 1.76 | # QB: 1
Revenue Correlation: 30.15 | Revenue CAGR: 47.64% | SUE: -0.12 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.32 | Chg30d=+0.004 | Revisions Net=+0 | Analysts=8
EPS next Year (2026-12-31): EPS=-1.19 | Chg30d=+0.025 | Revisions Net=-4 | Growth EPS=-0.9% | Growth Revenue=+8.9%